Bicocca Open Archive

Logo unimib boa
BIAGI, ETTORE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.766
EU - Europa 4.239
AS - Asia 4.106
SA - Sud America 586
AF - Africa 60
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 9
Totale 20.779
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.512
SG - Singapore 1.491
CN - Cina 1.186
SE - Svezia 716
RU - Federazione Russa 682
HK - Hong Kong 681
DE - Germania 611
UA - Ucraina 489
BR - Brasile 486
IE - Irlanda 466
IT - Italia 449
VN - Vietnam 356
GB - Regno Unito 267
CA - Canada 204
FI - Finlandia 128
FR - Francia 100
IN - India 85
KR - Corea 68
TR - Turchia 63
NL - Olanda 56
AR - Argentina 51
AT - Austria 51
BE - Belgio 45
DK - Danimarca 38
MX - Messico 38
PL - Polonia 36
ID - Indonesia 33
ES - Italia 32
BD - Bangladesh 29
ZA - Sudafrica 29
JP - Giappone 28
BG - Bulgaria 22
IQ - Iraq 19
EC - Ecuador 14
IR - Iran 11
EU - Europa 10
IL - Israele 10
RO - Romania 9
EG - Egitto 8
CH - Svizzera 7
CL - Cile 7
CO - Colombia 7
VE - Venezuela 7
AU - Australia 6
UY - Uruguay 6
AE - Emirati Arabi Uniti 5
CZ - Repubblica Ceca 5
MA - Marocco 5
PK - Pakistan 5
TN - Tunisia 5
UZ - Uzbekistan 5
AL - Albania 4
BY - Bielorussia 4
LT - Lituania 4
MU - Mauritius 4
RS - Serbia 4
AZ - Azerbaigian 3
HR - Croazia 3
JM - Giamaica 3
JO - Giordania 3
NP - Nepal 3
OM - Oman 3
PA - Panama 3
PE - Perù 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
KW - Kuwait 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TW - Taiwan 2
A1 - Anonimo 1
BH - Bahrain 1
CR - Costa Rica 1
FK - Isole Falkland (Malvinas) 1
GR - Grecia 1
KE - Kenya 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
NR - Nauru 1
PH - Filippine 1
PR - Porto Rico 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
Totale 20.777
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.605
Woodbridge 1.238
Ashburn 973
Fairfield 876
Singapore 861
Houston 820
Chandler 724
Wilmington 693
Hong Kong 678
Jacksonville 516
Dublin 457
Seattle 383
Frankfurt am Main 345
Cambridge 335
Dearborn 316
New York 222
Beijing 214
Princeton 194
Santa Clara 170
Los Angeles 141
Nanjing 135
Milan 128
Hefei 127
Ho Chi Minh City 95
Shanghai 87
Lawrence 85
Lachine 83
Dallas 79
Altamura 68
Seoul 62
Dong Ket 60
Hanoi 60
Moscow 60
Buffalo 59
Chicago 58
San Diego 47
São Paulo 47
Vienna 47
Brussels 43
The Dalles 41
Toronto 40
Nanchang 38
Council Bluffs 37
Boardman 35
Tianjin 34
Andover 33
Guangzhou 33
Lissone 33
Helsinki 31
Fremont 30
London 30
Shenyang 30
Warsaw 30
Montreal 29
Hebei 27
Mountain View 26
Hangzhou 25
Munich 25
Huizen 23
Stockholm 22
Changsha 21
Denver 21
Plovdiv 20
Rio de Janeiro 20
Zhengzhou 20
Brooklyn 19
Rome 19
Jinan 18
Ningbo 18
Ottawa 17
Salt Lake City 17
Jiaxing 16
Tokyo 16
Jakarta 15
Poplar 15
Atlanta 14
Falls Church 14
Kocaeli 14
Manchester 14
Nürnberg 14
Auburn Hills 13
Johannesburg 13
Mexico City 13
Philadelphia 13
University Park 13
Boston 12
Edmonton 12
Norwalk 12
Turku 12
Amsterdam 11
Da Nang 11
San Francisco 11
Columbus 10
Elk Grove Village 10
Taizhou 10
Brasília 9
Chennai 9
Detroit 9
Kunming 9
Nuremberg 9
Totale 14.406
Salva come PNG Salva come JPEG
Nome #
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients 419
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies 391
Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation 388
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 367
Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories 358
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System 352
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 346
Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring 337
GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease 331
Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133+ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy 328
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients 312
Interleukin-17-producing t-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation 309
TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia 302
T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy 301
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia 300
Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. 294
Immunotherapy of acute leukemia by chimeric antigen receptormodified lymphocytes using an improved Sleeping Beauty transposon platform 294
Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia 288
Stable Expression Of Chimeric Antigen Receptors (CARs) By Sleeping Beauty-Mediated Gene Transfer and Efficient Expansion Of Leukemia-Specific Cytokine-Induced Killer (CIK) Cells 277
Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation 272
Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population 271
Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells 270
Characterization of Plated Lysate Cultured Mesenchymal Stromal Cells and Their Potential Use in Tissue-Engineered Osteogenic Devices for the Treatment of Bone Defects 264
Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy 261
Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors 257
Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia 256
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study 254
Chimeric Antigen Receptors against CD33/CD123 antigens efficiently target primary Acute Myeloid Leukemia cells in vivo 250
Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives 244
Chimeric T-cell receptors: New challenges for targeted immunotherapy in hematologic malignancies 241
Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. 239
Immunosuppression does not affect human bone marrow mesenchymal stromal cell efficacy after transplantation in traumatized mice brain 239
Donor-derived CD19-targeted T cells in allogeneic transplants 238
Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versus-host disease 235
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor 234
GMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy 234
Upregulation of adhesion molecules on leukemia targets improves the efficacy of cytotoxic T cells transduced with chimeric anti-CD19 receptor 233
Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient 231
Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library 226
A life-threatening paediatric case of acute autoimmune haemolytic anaemia (AIHA) successfully cured by plasma-exchange and combined immunosuppressive treatment 225
TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission 224
Long-term effects of bone marrow transplantation on dental status in children with leukaemia 224
Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia 223
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes 221
Targeting of Acute Myeloid Leukemia by Cytokine-Induced Killer Cells Redirected with a Novel CD123-Specific Chimeric Antigen Receptor 221
Failure of interferon-γ pre-treated mesenchymal stem cell treatment in a patient with crohn's disease 221
Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells 217
Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis 216
Development of an alveolar bone regeneration protocol with mesenchyl stem cells for the therapy of severe bone resorption in periodontal disease 215
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 214
Cytokine Induced Killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors 213
Cell-based strategies to manage leukemia relapse: Efficacy and feasibility of immunotherapy approaches 212
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine 210
Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation device 209
T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells 208
Antigen-induced regulatory T cells 208
CD40 activation of BCP-ALL cells generates 11L-10-producing, 11L-12-defective APCs that induce allogeneic T-cell anergy 206
Febrile complications in the first 100 days after bone marrow transplantation in children: a single center's experience 204
Estudio experimental sobre la utilización de células madre humanas en la terapia de los defectos periodontales: resultados preliminares 197
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells 195
Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells 191
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. 190
Chimeric Antigen Receptor for Specific Targeting of Acute Myeloid Leukemia 190
Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes 188
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia 186
PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immuno-compromised pediatric patients. 184
Role of early diagnosis for a noninvasive treatment of pulmonary thromboembolism in leukemic children 183
Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia 181
Intrathecal chemotherapy with antineoplastic agents in children 178
The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs 177
Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells 177
Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer 170
Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia: A case report 170
Mechanical and infective central venous catheter-related complications: a prospective non-randomized study using Hickman and Groshong catheters in children with hematological malignancies 170
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis 168
A persistent severe autoimmune hemolytic anemia despite apparent direct antiglobulin test negativization 167
Basic biology and clinical application of multipotent mesenchymal stromal cells: from bench to bedside 157
From Bone Marrow Transplantation to Cellular Therapies: Possible therapeutic strategies in managing autoimmune disorders 157
CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia 156
New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future 154
In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia 153
Effectiveness of extracorporeal photochemotherapy in treating long-term refractory chronic graft-versus-host disease 152
New findings about the Interplay among Clarithromycin, Immune and Central Nervous Systems 150
In Vitro Comparison of Three Different Chimeric Receptor-modified Effector T-cell Populations for Leukemia Cell Therapy 149
A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 in Patients With High-risk Neuroblastoma 145
LONG TERM SURVIVAL AND EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT DEPENDENT ON IMMUNOSUPPRESSIVE TREATMENT. 142
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor 140
Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo 137
Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells 133
Phase I Trial of Vaccination With Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 and Lymphotactin 132
Mesenchymal stem/stromal cells: a new "cells as drugs" paradigm. Efficacy and critical aspects in cell therapy 129
Long term efficacy of human bone marrow mesenchymal stem cells in traumatized mice brain is not affected by immunosuppressive treatment 129
LONG TERM EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT AFFECTED BY IMMUNOSUPPRESSIVE TREATMENT. 107
LONG TERM EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT AFFECTED BY IMMUNOSUPPRESSIVE TREATMENT. 95
null 78
Totale 21.191
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.670
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.670
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.084 0 0 0 0 0 138 166 124 153 223 85 195
2021/20221.376 51 135 208 106 71 68 58 66 138 134 98 243
2022/20232.370 271 739 198 224 136 355 24 151 171 6 69 26
2023/20241.359 46 39 61 56 202 348 264 62 112 8 30 131
2024/20252.976 185 333 135 141 255 74 140 116 385 477 239 496
2025/20263.770 797 467 510 860 1.018 118 0 0 0 0 0 0
Totale 21.191